Soft Tissue Sarcoma Diagnostics Market: Introduction
Sarcomas are a heterogeneous group of rare cancers of mesenchymal origin. Soft tissue sarcoma is also a rare type of cancer that grows in tissues such as muscle, fat, blood vessels, nerves, tendons, and the lining of joints that support, connect, and surround other body parts. This soft tissue sarcoma can occur in any place in the body, but most commonly it occurs in the arms, legs, and abdomen. Here, surgical removal is the most common treatment, although radiation is also recommended depending upon the type, location, and size of the tumor.
Soft tissue sarcomas account for less than 1% of all cases of cancer. Soft tissue sarcoma has more than 70 subtypes, and affects both children and adults.
Biopsy is always needed in a sarcoma diagnosis to find out the type of soft tissue sarcoma. Diagnosis without a biopsy or an improper biopsy could make surgery difficult. Biopsy is the removal of a small quantity of tissue for examination under the microscope. Three major types of biopsies are needle biopsy, incisional biopsy, and excisional biopsy.
Key Drivers and Restrains in Soft Tissue Sarcoma Diagnostics Market
- Major drivers of the soft tissue sarcoma diagnostic market include increased rate of genetically transmitted diseases such as Gardener’s syndrome, tuberous sclerosis, familial intestinal polyposis, and Von Recklinghausen’s disease; or an increase in incidence rate
- These immune system disabilities, along with body exposure to some dangerous chemicals, and ionizing radiation, increase in awareness about health and technological advancements are boosting the market
- Novel therapies are required for perfect treatment with fewer side effects. Therefore, several companies are working on some pipeline therapies with more attention to TK inhibitors, antagonistic antibodies, and inhibitors of downstream molecules of PI3K, MAPK, and mTOR and pathways such as Selinexor (KPT-330) Karyopharm Therapeutics, Repretinib (DCC-2618) Deciphera Pharmaceuticals, GSK3377794: GlaxoSmithKline, BA3021: BioAtla, Tazemetostat: Epizyme.
- Ectopic fructose-1,6-biphosphotase 2 (FBP2) is a suppressor of soft tissue sarcoma. Enforced FBP2 expression slows down the growth of cells and tumors through different mechanisms. In one mechanism, the cytosolic FBP2 provokes elevated glycolysis associated with the Warburg effect, inhibiting sarcoma cell proliferation.
- According to the Connective Tissue Oncology Society, patients with soft tissue sarcoma had a high rate of complications with COVID-19, as a number of sarcoma treatments are highly immunosuppressive
North America to Capture Major Market Share
- In terms of region, the global soft tissue sarcoma market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
- In North America, the pandemic has significantly affected the U.S., which has led to disruptions in surgical procedures. Currently, precautionary measures are taken during surgical procedures, which would lead to steady market expansion
- North America currently captures the soft tissue sarcoma diagnosis market, and it is expected to continue for the next few years. A number of clinical trials are underway for soft tissue cancer therapies, especially in the U.S., which is expected to increase its market share in the near future. Each year in the U.S., about 13,190 people are diagnosed with one of the types of cancer. New cases in U.S. in 2021 are projected to be 13,460, and the estimated deaths are 5,350.
- Europe was the second largest market in 2021. Covid-19 pandemic has changed the old lifestyle. Therefore, numerous global regions have adapted to telemedicine for sarcoma, and the U.K. is ahead in this. Furthermore, other regions are adapting to advanced technology due to the increased awareness about cancer and its treatment.
- In Italy, a sarcoma group study ISG-STS1001 demonstrated better survival by neoadjuvant epirubicin plus ifosfamide than histology-tailored regimens for high-risk soft tissue sarcoma
- The soft tissue sarcoma diagnostics market in India is hampered by lack of technology, logistics, and workforce. Radiology training is very limited, especially in musculoskeletal radiology.
Key Payers Operating in Soft Tissue Sarcoma Diagnostics Market
Major players operating in the soft tissue sarcoma diagnostics market are listed below:
- Adaptimmune
- GE Healthcare
- Siemens Healthcare
- Shimadzu Corporation
- Philips Healthcare
- Hitachi Medical Corporation
- Hologic
- Esaote
- Toshiba Medical System Corporation
- Varian Medical Systems
Global Soft Tissue Sarcoma Diagnostics Market Research Scope
Global Soft Tissue Sarcoma Diagnostics market, by Type
- Angiosarcoma
- Dermatofibrosarcoma Protuberans
- Epithelioid Sarcoma
- Gastrointestinal Stroma Tumor
- Kaposi’s Sarcoma
- Others
Global Soft Tissue Sarcoma Diagnostics Market, by Diagnostic test
- Diagnostic Imaging Test
- X-ray
- Magnetic resonance imaging (MRI)
- Computed tomography (CT) scan
- Others
- Laboratory Tests
- Others
Global Soft Tissue Sarcoma Diagnostics Market, by End-user
- Hospitals
- Specialty Clinics/Centers
- Diagnostic Laboratories
- Others
Global Soft Tissue Sarcoma Diagnostics Market, by Region
- North America
- Europe
- Germany
- Italy
- U.K.
- Spain
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
